Products
Online Inquiry
Motesanib
Cat. No.:
0225LY-0769
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Add to basket
Product Overview
Description:
Motesanib is an oral receptor tyrosine kinase inhibitor that targets Ret, Kit, PDGFR, and VEGFR to suppress cellular proliferation and angiogenesis.
Synonym:
453562-69-1; N-(3,3-dimethylindolin-6-yl)-2-(pyridin-4-ylmethylamino)nicotinamide; N-(3,3-dimethyl-2,3-dihydro-1H-indol-6-yl)-2-[(pyridin-4-ylmethyl)amino]pyridine-3-carboxamide; N-(2,3-Dihydro-3,3-dimethyl-1H-indol-6-yl)-2-[(4-pyridinylmethyl)amino]-3-pyridinecarboxamide; N-(3,3-dimethylindolin-6-yl)-2-(4-pyridylmethylamino)nicotinamide
CAS No.:
453562-69-1
Compound CID:
11667893
Formula:
C22H23N5
Formula Weight:
373.45
Specification
Targets&IC50:
VEGFR2: 3 nM; VEGFR3: 6 nM; VEGFR1: 2 nM; c-Kit: 8 nM
Relative Density:
1.251 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Motesanib can be used in oncology research to investigate the multi-target inhibition of VEGF, PDGF, and KIT receptors.
Library Information
Target:
VEGFR; c-Kit
Receptor:
c-Kit; VEGFR1; VEGFR2; VEGFR3
Pathways:
Angiogenesis; Tyrosine kinase/adaptors
Plate Number:
AOCL-10
Plate Location:
h7
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
50 mg/mL; 133.89 mM
ALogP:
2.721
HBA_Count:
3
HBD_Count:
3
Rotatable Bond:
5
